Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2015

View Archived Issues

Anti-annexin II shows potential as a new biomarker for APS

Resverlogix closes license agreement, enters stock purchase agreement with Hepalink

Monopar partners with Cancer Research UK and Cancer Research Technology on HuATN-658

Allergan patents EP2 receptor agonists

Daiichi Sankyo describes LCAT activators

Sanofi reports dual GIPR/GLP-1R agonists

Sunovion Pharmaceuticals reports P2X4 negative modulators

Bristol-Myers Squibb presents HCV NS5B inhibitors

Epizyme and Celgene extend research collaboration

AstraZeneca divests global rights to Entocort

CB-5083 receives FDA orphan drug designation for multiple myeloma

FDA orphan drug designation granted to Rett's syndrome candidate sarizotan

Etodolac and propranolol combination receives U.S. orphan status for malignant glioma

Genentech's atezolizumab reduces tumor size in phase II urothelial bladder cancer study

sFLT-1 may enable early diagnosis of sickle cell nephropathy

FDA approves Rexulti for schizophrenia and major depressive disorder

Homocitrulline can differentiate acute and chronic renal failure

Canadian trial investigates novel tumor-targeted oncolytic virus vaccine

BioDiem and Griffith University receive grant to study targets of BDM-I

Galectin-3 may be a biomarker of cirrhosis severity

Imbruvica approved in E.U. for Waldenstrom's macroglobulinemia

The Scripps Research Institute to study environmental triggers for autoimmune disease

Novel hyaluronic acid eyedrops promote corneal tissue healing

Benitec acquires full rights to Hepbarna hepatitis B program

Novo Nordisk releases results from first phase IIIa study of semaglutide for type 2 diabetes

EyeGate licenses EGP-437 and delivery technology to Valeant

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...